← Eichor
Condition: Ret Gene Mutation Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Ret Gene Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors
Phase 4 · 2 location(s) · Rigel Pharmaceuticals · NCT07704658The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
Phase 1/Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT06109558Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
Phase 2 · 1 location(s) · Guangdong Provincial People's Hospital · NCT05800340
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.